Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2020
Date of Report: July 29, 2020
This filing serves as a cover document for a press release dated July 29, 2020 (Exhibit 99.1). The registrant is a French biopharmaceutical company headquartered in Marseille.
Key Financial Metrics
The provided filing text contains only the cover page and signature block for the Form 6-K. It does not include the content of the referenced press release or any financial statements.
- Revenue: Not provided in the filing text.
- Profit/Loss: Not provided in the filing text.
- Cash Flow: Not provided in the filing text.
- Debt and Liquidity: Not provided in the filing text.
- Margins: Not provided in the filing text.
Material Changes
The filing text does not provide specific data to compare against prior periods. The document references a press release (Exhibit 99.1) which likely contains the material information, but the text of that release is not included in the input.
Guidance, Outlook, and Risks
No management commentary, guidance, risk factors, or discussion of unusual items is present in the provided text. The filing is limited to administrative details and the signature of the Chief Financial Officer, Laure-Hélène Mercier.
Investor Verification Checklist
- Verify the content of Exhibit 99.1 (Press Release dated July 29, 2020) to obtain the actual news or financial data triggering this filing.
- Confirm the specific clinical or commercial milestone announced in the referenced press release.
- Review the company's most recent Form 20-F for baseline financial data, as this 6-K does not contain financial tables.